Compare Global X Defense Tech ETF (SHLD) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Defense Tech ETF vs Viatris Inc — how do they compare? Global X Defense Tech ETF trades at $60.34, while Viatris Inc trades at $17.15 (market cap $19.79B). The key difference: Viatris Inc pays a 2.83% dividend while Global X Defense Tech ETF pays none, and Viatris Inc is trading nearer its 52-week high, Global X Defense Tech ETF nearer its low. Which is the better fit depends on your goals.
| SHLD | VTRS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $78.02 | $17.39 |
52-Week Low | $58.20 | $8.74 |
Market Cap | — | $19.79B |
Enterprise Value | — | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SHLD trades at $60.03, down 0.05% on the day, with technical indicators showing a bearish trend from moving averages but neutral oscillators. The ETF focuses on global defense technology, benefiting from rising military budgets and geopolitical tensions. Recent news highlights institutional interest, including Decker Wealth Management's new position in Q1 2026, and analyst discussions on defense ETF comparisons amid sector tailwinds.
The outlook for SHLD is supported by structural growth in defense spending, but risks include political uncertainty and valuation concerns. Investors gain diversified exposure to defense tech innovation, though competition from other ETFs and expense ratios may impact relative performance. Near-term price action hinges on technical support at $59 and broader market sentiment toward defense stocks.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
